clinical trial · NCT07333261
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
Susan Bal·phase1·recruiting·n = 25
Multiple MyelomaBMS-986453
brief summary
This is a phase 1b study evaluating if BMS-986453 is safe and effective in treating people who have newly diagnosed multiple myeloma after completing initial therapy (induction) when a stem cell transplant is not intended.
started
Feb 9, 2026
primary completion
Dec 1, 2031
completion
Dec 1, 2041
last updated
Feb 13, 2026
detailed description
This is an open-label study. The investigators propose to examine if BMS-986453 in people with newly diagnosed multiple myeloma may help control their disease for a prolonged period of time despite one-time treatment and challenge continuous treatment which is otherwise prescribed.
official title
A Phase 1b Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Newly Diagnosed Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol